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Mats Lambe3,7, Lars Holmberg1,2,3 and Mieke Van Hemelrijck1,8*Abstract
Background: Observational studies have indicated that high calcium intake may prevent colorectal cancer, but as
for randomized trials the results are inconclusive. Meanwhile, limited data on the link between serum calcium and
cancer risk is available. We investigated the relation between serum calcium and risk of different gastrointestinal
cancers in a prospective study.
Methods: A cohort based on 492,044 subjects with baseline information on calcium (mmol/L) and albumin (g/L)
was selected from the Swedish Apolipoprotein MOrtality RISk (AMORIS) study. Multivariable Cox proportional hazard
models were used to analyse associations between standardised levels, quartiles and age/sex-specific categories of
serum calcium and risk of oesophageal, stomach, colon, rectal cancer and also colorectal cancer combined, while
taking into account serum albumin and other comorbidities.
Results: During 12 years of follow-up, we identified 323 incident oesophageal cancers, 782 stomach cancers, 2519
colon cancers, and 1495 rectal cancers. A positive association was found between albumin-adjusted serum calcium
and risk of oesophageal [HR: 4.82 (95% CI: 2.07 – 11.19) for high compared to normal age-specific calcium levels]
and colon cancer [e.g. HR: 1.07 (95% CI: 1.00 – 1.14) for every SD increase of calcium] as well as colorectal cancer
[e.g. HR: 1.06 (95% CI: 1.02-1.11) for every SD increase of calcium] in women. In men there were similar but weaker
non-statistically significant trends.
Conclusion: The positive relation between serum calcium, oesophageal cancer and colorectal cancer calls for
further studies including calcium regulators to evaluate whether there is a true link between calcium metabolism
and development of gastrointestinal cancer.
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A role of dietary calcium in colorectal cancer prevention
has been suggested [1], but there is lack of epidemio-
logical evidence linking serum calcium and gastrointes-
tinal cancer risk. High calcium intake has been shown to
suppress cell cycle, promote apoptosis and reduce for-
mation of colonic tumour in animal studies [2]. A
pooled analysis including 534,536 individuals from ten
cohort studies also revealed a lower colorectal cancer* Correspondence: mieke.vanhemelrijck@kcl.ac.uk
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distribution, and reproduction in any mediumrisk with higher calcium intake [3]. However, a random-
ized trial (n = 36,282) showed that daily supplementation
of calcium in combination with vitamin D for seven
years had no effect on colorectal cancer incidence
among postmenopausal women [4]. Meanwhile, no clear
association is known between dietary calcium intake and
risk of oesophageal cancer. Since calcium homeostasis is
mainly influenced by vitamin D and parathyroid hor-
mone (PTH) instead of dietary calcium [5], the use of
serum calcium may enable further insight into the rela-
tion between calcium metabolism and cancer risk. How-
ever, most available studies used uncorrected serum
calcium, whilst calcium levels are influenced by serum
albumin [6]. As calcium has also been linked to other
diseases [7], to what extent serum calcium is related tontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Reference levels of uncorrected calcium (mmol/L)
by age and sex
Men Women
< 40 years 2.22-2.60 2.17-2.56
40-60 years 2.20-2.59 2.19-2.60
≥ 60 years 2.19-2.58 2.21-2.60
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count serum albumin and other co-morbidities warrants
further investigation.
Methods
Study population and data collection
The Swedish AMORIS database has been described in
detail elsewhere [8-14]. Briefly, this database is based on
the linkage of the Central Automation Laboratory
(CALAB) database (1985–1996) to several Swedish na-
tional registries such as the National Cancer Register, the
National Patient Register, the Cause of Death Register,
the consecutive Swedish Censuses during 1970–1990,
and the National Register of Emigration by using the
Swedish 10-digit personal identity number to provide
information on socio-economic status (SES), vital status,
cancer diagnosis, and emigration. The CALAB database
includes data from 351,487 male and 338,101 female
healthy individuals having clinical laboratory testing as
part of a general health check-up or outpatients referred
for laboratory testing. No individuals were inpatients at
the time their blood samples were taken and none were
excluded for disease symptoms or because of treatment.
This study complied with the Declaration of Helsinki, and
the ethics review board of the Karolinska Institute
approved the study.
From the AMORIS database, we selected all persons
aged 20 years or older at baseline, whose serum levels of
calcium (mmol/L) and albumin (g/L) were measured at
baseline (n = 492,044). Of these, a total of 63,028 had an
additional baseline measurement of body-mass index
(BMI, kg/m2). Follow-up time was defined for each sub-
ject as the time from measurement until the date of GI
cancer diagnosis, emigration, death, or study closing date
(31st of December 2002), whichever occurred first. The
CALAB database also contained information on age at
index measurement. All other information was obtained
from the above mentioned national registries. SES was
taken from the Censuses and is based on occupational
groups and classifies gainfully employed subjects into
manual workers and non-manual employees, below
designated blue-collar and white-collar workers [15]. We
also calculated the Charlson co-morbidity index (CCI) by
using the information from the National Patient Register.
The CCI consists of 18 groups of diseases with a specific
weight assigned to each disease category [1-3,6]. These
weights were then summed to obtain an overall score,
resulting in four co-morbidity levels (0, 1, 2, and 3+) indi-
cating a scale ranging from no co-morbidity to severe co-
morbidity.
Ionized serum calcium level is a direct measure of the
amount of metabolically active serum calcium but is not
routinely measured [16]. Correction of total calcium
levels based on serum albumin is used to obtain anestimate of the free ionized calcium level, since almost
half (40%) of serum calcium is in protein-bound form
and alteration of serum albumin due to certain diseases
or dietary patterns may thus affect the levels of free ion-
ized calcium [5,16]. A colorimetric method was used for
the measurement of total serum calcium (coefficient of
variation <2.5%), whereas albumin was measured with a
bromcresolgreen (BCG) method (coefficient of variation
<1.8%). We corrected the calcium levels to the concen-
tration as if the albumin level was normal, meaning that
for every 1 g/L that the albumin concentration was
below 40 g/L (normal concentration), the calcium con-
centration was increased with 0.02 mmol/L [16]. All
levels were standardized according to the World Health
Organization International Federation of Clinical Chem-
ists protocols and all methods were fully automated with
automatic calibration and performed at one accredited
laboratory [8,17].
Levels of uncorrected calcium were also categorized into
three categories (low, normal, high) based on whether it
was below, equal, or above the reference interval used in
CALAB laboratory. This reference interval differed by age
and sex (Table 1).
Data analysis
The associations between levels of serum calcium, age-
specific calcium, albumin-corrected calcium and risk of
incident GI cancer were analyzed with multivariate Cox
proportional hazards models. A test for trend was
conducted by using assignment to categories as an or-
dinal scale. All models took into account age at index
measurements. When studying the association between
crude calcium and gastrointestinal cancer risk, we also
adjusted the Cox proportional hazards models for albu-
min levels as a continuous variable. Additional adjust-
ments were performed for gender, SES, and CCI.
Analyses were repeated in men and women separately to
further evaluate gender effects. We considered the prob-
ability of reverse causation (i.e. calcium levels can be af-
fected by an undiagnosed gastrointestinal cancer) by
conducting a sensitivity analysis in which the first three
years of follow-up were excluded (n = 9,171). Addition-
ally, we did a stratified analysis by BMI (</≥25 kg/m2),
as it was shown previously that the association between
calcium and cancer risk is possibly modified by levels of
BMI [18].
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history and mainly seen in the elderly, thus competing
risks are involved in the analysis of gastrointestinal cancer
risk. A competing risk situation arises when an individual
can not only experience the event of interest, but also be
censored due to other events [19]. It is even more import-
ant to consider competing risk when, as in this study, the
exposure of interest may be linked to both gastrointestinal
cancer and early death. Thus, death from other causes is
considered to be competing risks for gastrointestinal
cancer diagnosis. In a Cox proportional hazard model, as
described above, one of the main assumptions is that cen-
soring is non-informative. We violate this assumption
when we censor for death (and not having gastrointestinal
cancer) if death is related to our exposure of interest, cal-
cium levels. To evaluate whether competing risks may be
affecting our findings, we calculated proportional hazards
models in which we censored for gastrointestinal cancer





(n = 323) (n = 7
Age (years) - Mean (SD) 56.07 (10.63) 58.72 (1
Sex
Male 237 (71.39) 501 (62
Female 95 (28.61) 301 (37
SES
White Collar 112 (33.73) 262 (32
Blue Collar 162 (48.80) 359 (44
Not gainfully employed or Missing 58 (17.47) 181 (22
Follow-up time (years) - Mean (SD) 8.06 (4.71) 7.73 (4
Calcium (mmol/L) - Mean (SD) 2.40 (0.11) 2.38 (0
Calcium according to age-specific cut-offs
Low 2 (0.60) 9 (1.1
Normal 320 (96.39) 778 (97
High 10 (3.10) 15 (1.
Corrected Calcium (mmol/L) - Mean (SD) 2.35 (0.10) 2.34 (0
Albumin (g/L) Mean (SD) 42.11 (2.97) 41.82 (
BMI (kg/m2)1
< 25 17 (58.62) 40 (50
≥ 25 12 (41.38) 39 (49
Charlson Comorbidity Index
0 273 (82.23) 666 (83
1 30 (9.04) 77 (9.
2 19 (5.72) 42 (5.
3+ 10 (3.01) 17 (2.
1Measured in subcohort with BMI measurement.Moreover, we conducted a case-only survival analysis for
gastrointestinal cancer outcomes, while also adjusting for
the time between measurement of calcium and gastro-
intestinal cancer diagnosis. For these analyses, follow-up
was defined as the time from gastrointestinal cancer diag-
nosis until the date of gastrointestinal cancer death, emi-
gration, death, or study closing date (31 December 2002),
whichever occurred first.
All P-values were two-sided and all analyses were
conducted with Statistical Analysis Systems (SAS) release
9.1.3 (SAS Institute, Cary, NC).
Results
A total of 323 cases of incident oesophageal cancers, 782
stomach cancers, 2519 colon cancers, 1495 rectal cancers,
and a combined 4014 colorectal cancer were identified
during follow-up (mean: 12.5 years). Study population
characteristics are shown in Table 2. The Pearson correl-










82) (n = 2519) (n = 1495) (n = 4014) (n = 492044)
1.80) 58.93 (11.61) 57.38 (11.02) 58.36 (11.42) 44.62 (14.11)
.47) 1394 (54.09) 926 (60.76) 2320 (56.57) 260469 (52.94)
.53) 1183 (45.91) 598 (39.24) 1781 (43.43) 231575 (47.06)
.67) 946 (36.71) 583 (38.25) 1529 (37.28) 182488 (37.09)
.76) 1063 (41.25) 684 (44.88) 1747 (42.60) 231088 (46.96)
.57) 568 (22.04) 257 (16.86) 825 (20.12) 78468 (15.95)
.62) 8.46 (4.64) 8.44 (4.51) 8.46 (4.59) 12.55 (3.94)
.10) 2.39 (0.10) 2.39 (0.10) 2.39 (0.10) 2.39 (0.10)
2) 17 (0.66) 13 (0.85) 30 (0.73) 4025 (0.82)
.01) 2508 (97.32) 1477 (96.92) 3985 (97.17) 479026 (97.35)
87) 52 (2.02) 34 (2.23) 86 (2.10) 8993 (1.83)
.09) 2.35 (0.09) 2.34 (0.09) 2.35 (0.09) 2.32 (0.09)
2.75) 41.92 (2.69) 42.28 (2.68) 42.05 (2.69) 43.18 (2.84)
.63) 141 (50.72) 96 (55.49) 237 (52.55) 38517 (61.11)
.37) 137 (49.28) 77 (44.51) 214 (47.45) 24511 (38.89)
.04) 2199(85.33) 1312 (86.09) 3511 (85.61) 454237 (92.32)
60) 190 (7.37) 113 (7.41) 303 (7.39) 20669 (4.20)
24) 143 (5.55) 77 (5.05) 220 (5.36) 12869 (2.62)
12) 45 (1.75) 22 (1.44) 67 (1.63) 4269 (0.87)
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and albumin-corrected calcium.
First, to investigate the relation between calcium and
gastrointestinal cancer, we used different measurements
of calcium in age-adjusted Cox proportional hazard
models (Table 3). An inverse trend was observed between
quartiles of serum calcium and risk of stomach and colon
cancers in the age-adjusted models [e.g. HR for colon can-
cer 0.92 (95% CI: 0.82 – 1.02), 0.94 (0.84 – 1.05), and 0.88
(0.79 – 0.98) for the 2nd, 3rd, and 4th quartiles of calcium,
respectively; P-value for trend 0.03]. A similar but border-
line association was also seen between calcium and colo-
rectal cancer, while no apparent link was observed for
oesophageal cancer and rectal cancer alone. Interestingly,
this inverse trend was not evident after adjustment for
gender, SES, albumin, and CCI. For calcium based on age-
specific cut-offs, a statistically significant association was
only observed with colorectal cancer risk after adjustment
with gender, SES, albumin, and CCI [HR: 1.27 (95% CI:
1.03-1.58) for those with high age-specific calcium levels
compared to normal].
When using albumin-corrected calcium, we found a
higher risk of colon cancer in those in higher albumin-
corrected calcium quartiles., Additional adjustments for
gender, SES, and CCI resulted in a stronger association
with colon cancer risk [HR for colon cancer: 1.13 (95% CI:
0.99 – 1.28), 1.10 (0.98 – 1.28), and 1.16 (1.06 – 1.34) for
the 2nd, 3rd, and 4th quartiles of calcium, respectively;
P-value for trend 0.007] and a statistically significant asso-
ciation with colorectal cancer risk [e.g. HR for colorectal
cancer: 1.09 (95% CI: 0.99 – 1.21), 1.09 (0.99 – 1.20), and
1.13 (1.03 – 1.34) for the 2nd, 3rd, and 4th quartiles of cal-
cium, respectively; P-value for trend 0.02].
When analyzing men and women separately while
adjusting for serum albumin, we observed a similar but
non-statistically significant relation with serum calcium
for men (Table 4). For women, those with high age-
specific calcium levels are at higher risks for developing
oesophageal cancer [e.g. HR: 4.82 (95% CI: 2.07-11.19) for
high age-specific calcium compared to normal]. Similar to
the results in men and women combined, a statistically
significant association with risk of colon cancer was ob-
served in women [HR: 1.07 (95% CI: 1.00 – 1.14) for every
SD increase in serum calcium]. Using albumin-corrected
calcium, we found a positive link with with colon as well
as colorectal cancer risk in women [e.g. HR for colon and
colorectal cancer: 1.07 (95% CI: 1.02-1.13) and 1.06 (95%
CI: 1.02-1.11) for every SD increase in corrected calcium,
respectively]. A sensitivity analysis excluding those with
follow-up less than 3 years did not substantially alter these
findings (results not shown).
Next, we assessed the risk of death as a competing risk
while censoring for gastrointestinal cancer in the models.
We found a statistically significant association betweenserum calcium and risk of death [e.g. HR: 1.14 (1.13 –
1.15) for every SD increase in calcium; results not shown
in tables]. When using the age-specific calcium levels, we
observed higher risks of death in those with both low and
high serum calcium [HR: 1.26 (95% CI: 1.15 – 1.37) and
1.47 (1.39 – 1.57) for low and high age-specific calcium
levels, respectively].
We also investigated the relation between calcium and
gastrointestinal cancer risk while stratifying for over-
weight status (</≥25 kg/m2) in a subcohort with baseline
BMI. However this resulted in low statistical power of
our analyses (Table 5). A statistically significant associ-
ation was only observed for oesophageal cancer in those
with BMI < 25 kg/m2 [HR: 1.92 (95% CI: 1.32-2.82) for
every SD increase in albumin-corrected calcium].
Finally, we estimated risk of fatal gastrointestinal cancer
by assessing risk of cancer-specific death in those diag-
nosed with gastrointestinal cancer. No statistically signifi-
cant association was found in these models (results not
shown). We also performed a sensitivity analysis for
gastrointestinal cancer diagnosed < 3 years after baseline
measurements, but this did not affect our results (results
not shown).
Discussion
The present study showed a lower risk of colon cancer in
those in higher serum calcium quartiles but higher risk for
rectal cancer in those with high age-specific calcium levels.
However, correction with albumin or adjustment for
gender, SES, albumin and CCI revealed a positive link
between serum calcium and colon as well as colorectal
cancer risk, particularly in women. Additionally, we found
a persistent positive link between serum calcium and
oesophageal cancer risk, but this trend was not observed
in overweight individuals.
The role of diet in the aetiology of gastrointestinal
malignancies has been an emerging subject of research.
In animal studies, a Western-style diet with decreased
calcium and vitamin D was shown to induce formation
of intestinal tumours in normal mice during long-term
observation, although no marked difference was seen
from those treated with a standard diet [20,21]. Low
calcium diets have been linked to enhanced cyclin D1
and Bcl-2 expression and decreased Bax expression,
suggesting the modulation of cell cycle and apoptosis to
play a part in increased tumourigenesis [2]. Dietary
calcium may affect gastrointestinal malignancy directly
via activation of calcium-sensing receptor (CaR) and
binding of bile acids in gastrointestinal tract, and indir-
ectly by increasing serum calcium levels [1,22]. A dual
effect of luminal calcium on colon cells have been ob-
served, where it promotes differentiation and apoptosis
of normal colon cells progenitor, but becomes ineffective
or even tumor-promoting in carcinogenesis [23]. On the
Table 3 Hazard ratios and 95% confidence intervals (CI) for the association between calcium (age-specific and albumi corrected) and risk of gastrointestinal
cancer







































































































P-value for trend 0.61 0.09 0.04 0.95 0.03 0.56 0.08 0.71 0.05 0.51































































Quartiles of albumin-corrected calcium2





























































P-value for trend 0.11 0.05 0.72 0.86 0.03 0.007 0.99 0.61 0.12 0.02
All models are adjusted for age at index measurement.
1Adjusted for sex, SES, albumin (continuous), and Charlson comorbidity index.



































Table 4 Hazard ratios and 95% confidence intervals (CI) for the association between calcium and risk of
gastrointestinal cancer in men and women
Men (N = 260,469)
Oesophageal cancer Stomach cancer Colon cancer Rectal cancer Colorectal cancer
n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI)
Calcium (SD: 0.10 mmol/L) 1.13 (0.98-1.30) 0.94 (0.85-1.04) 1.02 (0.96-1.08) 1.03 (0.96-1.11) 1.02 (0.98-1.07)
Quartiles of calcium
< 2.33 62 1.00 (Ref) 143 1.00 (Ref) 389 1.00 (Ref) 223 1.00 (Ref) 612 1.00 (Ref)
2.33-2.39 62 0.89 (0.62-1.27) 171 1.13 (0.90-1.41) 407 0.96 (0.84-1.11) 282 1.10 (0.92-1.32) 689 1.01 (0.91-1.13)
2.39-2.45 57 1.00 (0.68-1.45) 99 0.84 (0.64-1.09) 352 1.05 (0.90-1.22) 236 1.12 (0.92-1.35) 588 1.07 (0.96-1.21)
≥ 2.45 56 1.25 (0.84-1.86) 88 0.99 (0.74-1.31) 246 0.96 (0.81-1.15) 185 1.10 (0.89-1.36) 431 1.02 (0.89-1.16)
P-value for trend 0.24 0.40 0.97 0.36 0.55
Calcium according to age-specific cut-offs
Low 1 0.56 (0.08-4.00) 4 0.92 (0.34-2.48) 7 0.62 (0.29-1.30) 9 1.47 (0.78-2.86) 16 1.01 (0.97-1.06)
Normal 232 1.00 (Ref) 487 1.00 (Ref) 1360 1.00 (Ref) 895 1.00 (Ref) 2255 1.00 (Ref)
High 4 1.03 (0.38-2.78) 10 1.27 (0.67-2.38) 27 1.21 (0.83-1.78) 22 1.36 (0.89-2.09) 49 0.92 (0.56-1.51)
Albumin-corrected calcium1
(SD: 0.09 mmol/L) 1.14 (1.00-1.29) 0.98 (0.89-1.07) 1.04 (0.98-1.10) 1.03 (0.97-1.11) 1.04 (0.99-1.08)
Quartiles of albumin-corrected calcium1
< 2.27 50 1.00 (Ref) 110 1.00 (Ref) 258 1.00 (Ref) 187 1.00 (Ref) 445 1.00 (Ref)
2.27-2.33 40 0.75 (0.49-1.13) 106 0.89 (0.68-1.16) 316 1.12 (0.95-1.32) 204 1.01 (0.83-1.23) 520 1.08 (0.95-1.22)
2.33-2.38 64 0.97 (0.67-1.40) 134 0.91 (0.71-1.17) 378 1.09 (0.93-1.28) 260 1.05 (0.87-1.26) 638 1.07 (0.95-1.21)
≥ 2.38 83 1.16 (0.82-1.65) 151 0.93 (0.73-1.19) 442 1.17 (1.00-1.36) 275 1.02 (0.85-1.23) 727 1.11 (0.98-1.25)
P-value for trend 0.17 0.68 0.08 0.76 0.12
Women (N = 231,575)
Calcium (SD: 0.10 mmol/L) 1.25 (1.04-1.51) 1.07 (0.95-1.20) 1.07 (1.00-1.14) 1.04 (0.96-1.13) 1.06 (1.01-1.11)
Quartiles of calcium
< 2.32 21 1.00 (Ref) 58 1.00 (Ref) 211 1.00 (Ref) 113 1.00 (Ref) 324 1.00 (Ref)
2.32-2.38 23 0.98 (0.54-1.79) 77 1.12 (0.79-1.58) 302 1.17 (0.98-1.40) 147 1.04 (0.82-1.34) 449 1.13 (0.98-1.30)
2.38-2.44 18 0.80 (0.42-1.55) 66 0.98 (0.68-1.41) 300 1.17 (0.97-1.40) 160 1.12 (0.88-1.44) 460 1.15 (0.99-1.33)
≥ 2.44 33 1.30 (0.71-2.38) 100 1.25 (0.88-1.77) 370 1.18 (0.99-1.42) 178 1.01 (0.78-1.30) 548 1.12 (0.97-1.30)
P-value for trend 0.32 0.30 0.13 0.90 0.19
Calcium according to age-specific cut-offs
Low 1 0.70 (0.10-5.16) 5 1.44 (0.59-3.53) 10 0.76 (0.41-1.43) 4 0.66 (0.25-1.78) 14 0.73 (0.43-1.24)
Normal 88 1.00 (Ref) 291 1.00 (Ref) 1148 1.00 (Ref) 582 1.00 (Ref) 1730 1.00 (Ref)
High 6 4.82 (2.07-11.19) 5 1.02 (0.42-2.48) 25 1.30 (0.87-1.94) 12 1.19 (0.67-2.11) 37 1.26 (0.91-1.75)
Albumin-corrected calcium1
(SD: 0.09 mmol/L) 1.26 (1.06-1.50) 1.08 (0.97-1.20) 1.07 (1.02-1.13) 1.04 (0.96-1.12) 1.06 (1.02-1.11)
Quartiles of albumin-corrected calcium1
< 2.27 9 1.00 (Ref) 36 1.00 (Ref) 134 1.00 (Ref) 75 1.00 (Ref) 209 1.00 (Ref)
2.27-2.32 20 1.46 (0.67-3.22) 67 1.20 (0.80-1.80) 250 1.17 (0.95-1.45) 133 1.15 (0.86-1.52) 383 1.16 (0.98-1.38)
2.32-2.38 23 1.45 (0.66-3.15) 66 1.00 (0.66-1.51) 302 1.19 (0.97-1.47) 159 1.18 (0.89-1.55) 461 1.19 (1.01-1.40)
≥ 2.38 43 1.87 (0.89-3.91) 132 1.34 (0.92-1.96) 497 1.32 (1.08-1.60) 231 1.17 (0.89-1.53) 728 1.26 (1.08-1.48)
P-value for trend 0.09 0.15 0.007 0.34 0.006
All models are adjusted for age, SES, albumin (continuous), and Charlson comorbidity index.
1Not adjusted for albumin.
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Table 5 Hazard ratios and 95% confidence intervals (CI) for the association between calcium and risk of GI cancer,
stratified by overweight (BMI</≥25 kg/m2) in sub-cohort with baseline measurements of BMI
Not Overweight (N = 24,511)
Oesophageal cancer Stomach cancer Colon cancer Rectal cancer Colorectal cancer
n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI)
Calcium (SD: 0.10 mmol/L) 2.02 (1.33-3.07) 0.81 (0.57-1.14) 1.01 (0.84-1.21) 1.10 (0.88-1.38) 1.04 (0.91-1.21)
Quartiles of calcium
< 2.32 3 1.00 (Ref) 13 1.00 (Ref) 34 1.00 (Ref) 18 1.00 (Ref) 52 1.00 (Ref)
2.32-2.38 3 1.04 (0.20-5.30) 11 0.67 (0.28-1.51) 42 1.08 (0.68-1.71) 28 1.72 (0.72-2.38) 70 1.05 (0.91-1.21)
2.38-2.45 4 1.86 (0.39-8.87) 7 0.53 (0.20-1.37) 33 1.07 (0.65-1.75) 30 1.74 (0.95-3.20 63 1.15 (0.87-1.52)
≥ 2.45 7 3.28 (0.73-14.71) 9 0.58 (0.23-1.47) 32 0.91 (0.54-1.55) 20 1.03 (0.52-2.04) 52 0.57 (0.34-0.96)
P-value for trend 0.07 0.21 0.73 0.74 0.95
Albumin-corrected calcium1 1.93 (1.32-2.82) 1.03 (0.61-1.14) 1.02 (0.86-1.21) 1.10 (0.90-1.35) 1.05 (0.93-1.20)
(SD: 0.09 mmol/L)
Quartiles of albumin-corrected calcium1
< 2.27 2 1.00 (Ref) 8 1.00 (Ref) 23 1.00 (Ref) 16 1.00 (Ref) 39 1.00 (Ref)
2.27-2.33 2 0.90 (0.13-6.84) 10 1.08 (0.42-2.73) 31 1.20 (0.70-2.05) 19 1.03 (0.53-2.00) 50 1.13 (0.74-1.71)
2.33-2.39 3 1.06 (0.18-6.37) 12 1.04 (0.42-2.55) 42 1.30 (0.78-2.16) 29 1.26 (0.68-2.33) 71 1.28 (0.87-1.90)
≥ 2.39 10 2.94 (0.64-13.65) 10 0.71 (0.28-1.80) 45 1.12 (0.67-1.86) 32 1.14 (0.62-2.09) 87 1.13 (0.76-1.66)
P-value for trend 0.07 0.42 0.72 0.58 0.53
Overweight (N = 38,517)
Calcium (SD: 0.10 mmol/L) 0.69 (0.38-1.28) 1.04 (0.74-1.46) 0.97 (0.81-1.16) 0.98 (0.77-1.25) 0.97 (0.84-1.13)
Quartiles of calcium
< 2.31 5 1.00 (Ref) 11 1.00 (Ref) 35 1.00 (Ref) 18 1.00 (Ref) 53 1.00 (Ref)
2.31-2.37 3 0.61 (0.14-2.61) 8 0.66 (0.26-1.65) 35 0.85 (0.53-1.37) 22 1.01 (0.54-1.90) 57 0.91 (0.60-1.32)
2.37-2.44 1 0.27 (0.03-2.36) 11 1.08 (0.45-2.58) 39 1.09 (0.68-1.75) 16 0.82 (0.41-1.64) 55 0.99 (0.67-1.47)
≥ 2.44 3 1.00 (0.21-4.78) 9 1.00 (0.38-2.60) 28 0.83 (0.48-1.42) 21 1.09 (0.55-2.17) 49 0.92 (0.61-1.41)
P-value for trend 0.72 0.52 0.76 0.94 0.85
Albumin-corrected calcium1
(SD: 0.09 mmol/L) 0.77 (0.44-1.35) 1.06 (0.78-1.45) 0.99 (0.84-1.17) 0.99 (0.79-1.23) 0.99 (0.86-1.13)
Quartiles of albumin-corrected calcium1
< 2.27 3 1.00 (Ref) 8 1.00 (Ref) 24 1.00 (Ref) 15 1.00 (Ref) 39 1.00 (Ref)
2.27-2.33 3 0.77 (0.15-3.82) 7 0.65 (0.24-1.79) 31 0.94 (0.55-1.60) 15 0.72 (0.35-1.48) 46 0.85 (0.56-1.31)
2.33-2.39 3 0.73 (0.15-3.65) 9 0.81 (0.31-2.10) 43 1.26 (0.76-2.08) 23 1.08 (0.56-2.08) 66 1/13 (0.80-1.77)
≥ 2.39 3 0.65 (0.13-3.29) 15 1.15 (0.48-2.75) 39 0.95 (0.57-1.59) 24 0.92 (0.48-1.77) 63 0.94 (0.63-1.41)
P-value for trend 0.62 0.52 0.90 0.84 0.83
All models are adjusted for age, sex, SES, albumin (continuous), and Charlson Comorbidity Index.
1 Not adjusted for albumin.
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cinogenesis remains indefinite. It is suggested that the
rise of extracellular calcium results in increased cytosolic
levels of calcium, which subsequently affects multiple
cellular processes including cell cycle and apoptosis,
possibly via Ras and β-catenin pathways [22,24].
Despite the above pre-clinical findings, the effects of
calcium metabolism on gastrointestinal cancer develop-
ment in human are not fully understood yet. Extensive
epidemiological evidence has indicated the protectiverole of dietary calcium against both colorectal adenoma
and invasive colorectal cancer [3,25-27]. However little
evidence exists to explain the effects of serum calcium
on gastrointestinal cancer, or whether similar effects on
cancer risks are shared by dietary and serum calcium. In
clinical studies, calcium supplementation in persons
with resected colorectal adenomatous polyp has been
linked to increased Bax expression in polyp interiors,
suggesting enhanced apoptosis as the mechanism op-
posing carcinogenesis [28]. Randomized controlled
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cium and vitamin D supplementation showed similar
findings [5,29], as well as a lower colorectal adenoma
recurrence compared to the placebo group [23]. On the
other hand, a meta-analysis assessing two clinical trials
with supplementation of calcium and vitamin D in
population without increased baseline risks revealed no
difference in colorectal cancer incidence between post-
menopausal women with and without treatment [30],
indicating different mechanisms linking calcium to
colorectal adenoma and invasive cancer albeit not con-
firmed using serum calcium yet.
Calcium was statistically significantly correlated to albu-
min in the present study, which may explain the different
patterns of association with and without adjustment or
correction of serum calcium. After taking albumin into ac-
count, a positive association was observed between serum
calcium and risk of oesophageal and colon cancer in
women, as opposed to the suggested inverse relation
between dietary calcium and colorectal cancer, and a lack
of association with oesophageal cancer [3,31]. Although
dietary calcium is a major determinant of total body cal-
cium balance, serum calcium reflects extracellular calcium
homeostasis and is mainly affected by vitamin D and
PTH, thus abnormalities in serum calcium may reflect a
defect in its regulation processes rather than lack of diet-
ary calcium [5]. This may results in different associations
between dietary and serum calcium and carcinogenesis.
High serum levels of calcium may follow from hyperpara-
thyroidism or high serum vitamin D levels which may
then suppress production of another hormonal regulator,
FGF23, and lead to down-regulation of klotho, a cancer
prevention protein [32]. Furthermore, a true inverse asso-
ciation may have been masked as high serum calcium is
associated with death from other diseases such as cardio-
vascular diseases [7].
In the present study, we assessed risk of death while
censoring those diagnosed with gastrointestinal cancer.
We found a strong association between calcium and risk
of death from other diseases, indicating that gastrointes-
tinal cancer is competing with other causes of death.
This highlighted the importance of including other
comorbidities as measured by CCI in the analyses to
minimize the effects of competing risk on the associ-
ation between calcium and gastrointestinal cancer.
Corroborating the suggested link between calcium and
obesity in the context of cancer [33], we found markedly
different risk estimates for oesophageal cancer when
stratifying according to overweight status [e.g. HR: 1.93
(95% CI: 1.32-2.82) and 0.77 (0.44-1.35) for every SD
increase of albumin-corrected calcium in normoweight
and overweight individuals, respectively]. However the
limited samples resulted in a low statistical power in this
analysis, which explained weaker associations observedin this subcohort compared to the overall study popula-
tion. Therefore increasing the number of samples with
available baseline BMI is essential in studying the link
between calcium, obesity, and gastrointestinal cancer in
future studies.
We also investigated risk of fatal gastrointestinal
cancer using cancer-specific death as an outcome in
those diagnosed with gastrointestinal cancer. No ap-
parent link between different measurements of calcium
and gastrointestinal cancer death was observed, which
may be partly a result of small number of fatal cancer
in these subgroups. Additionally, there is a consider-
able lag time between baseline measurements and
diagnosis of gastrointestinal cancer. Calcium measure-
ments closer to diagnosis date may provide a better
assessment of gastrointestinal cancer death, but also at
risk of being influenced by the course of the disease.
The major strength of these analyses lies in the large
number of men with prospective measurements of
calcium, albumin, and glucose in AMORIS, all measured
at the same clinical laboratory. To our knowledge this is
the only prospective study on gastrointestinal cancer risk
with information on calcium and albumin as well as
other comorbidities. Nevertheless, a direct measure of
serum ionized calcium should have been preferable but
is seldom used in clinical practice due to high measure-
ment costs but albumin-corrected serum calcium is a
valid assessment of ionized calcium on a group level
[16]. This database provided complete follow-up for
each person as well as linkage to other registers allowing
for detailed information on cancer diagnosis, time of
death, and emigration. The AMORIS population was se-
lected by analysing blood samples from health check-ups
in non-hospitalised individuals. The AMORIS cohort is
similar to the general working population of Stockholm
in terms of SES and ethnicity. During the study period
all-cause mortality was about 14% lower in the AMORIS
population than in the general population of Stockholm
county when taking age, gender, and calendar year into
account [34]. This selection of a healthy cohort does
however not affect the internal validity of our study. To
account for detection bias, we adjusted all analyses for
other comorbidities (CCI). High serum levels of calcium
can bias the results because these persons receive more
intensive medical care (e.g. increased number of clinical
visits due to other diseases and symptoms related to
high calcium levels [5] and are thus more likely to be di-
agnosed with gastrointestinal cancer when it occurs. It is
also possible that gastrointestinal cancer events are
underestimated due to “early death” from other diseases
related with high serum levels of calcium, such as car-
diovascular death [7]. However, age-stratified analyses
with additional adjustments for the CCI minimized the
possible effect of competing risks. A restriction of this
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confines the statistical power of our stratified analyses.
There was also no information available on potential
confounders such as supplemental use of vitamin D
and/or calcium. Furthermore, we were unable to account
for the effect of dietary calcium on gastrointestinal car-
cinogenesis as suggested in biological studies [23]. There
was also no information available on tumour grade, stage,
or histology making it impossible to assess the association
between calcium and tumour severity, but gastrointestinal
cancer-specific death can be seen as a proxy for tumour
severity.
Conclusion
Serum calcium was positively associated to risk of
oesophageal and colon cancer alone as well as colorectal
cancer in women, opposing prior evidence from nutri-
tional studies. This may be caused by different biological
mechanisms linking dietary calcium and serum calcium
with gastrointestinal carcinogenesis. Our findings also
suggest that adjustment or correction based on albumin
is important in observing the true association between
calcium and gastrointestinal cancer risks. Finally, future
studies on the role of calcium metabolism and gastro-
intestinal cancer development need to assess not only
serum calcium but also dietary intake and factors regulat-
ing calcium homeostasis, e.g. serum vitamin D and PTH.
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